<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02432911</url>
  </required_header>
  <id_info>
    <org_study_id>IHBDH-IIT2015003</org_study_id>
    <nct_id>NCT02432911</nct_id>
  </id_info>
  <brief_title>Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old</brief_title>
  <official_title>A Multicenter，Open-label，Randomized Study on the Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jianxiang Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study focus on the comparison of CAG regimen to the low dose cytarabine therapy in
      elderly AML patients who are unfit or unwilling to receive intensive chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low dose cytarabine remains to be the choice of standard for elderly AML patients who are
      unfit or unwilling to receive intensive treatment. CAG regimen, which is a combination of
      aclacinomycin，low dose cytarabine±G-CSF is used often in elderly AML patients in China. It is
      proved effective and safety in some pilot studies，while there is no prospective，randomized
      study yet.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related mortality</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>CAG regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose cytarabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cytarabine 20mg bid for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)</intervention_name>
    <description>Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.</description>
    <arm_group_label>CAG regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose cytarabine</intervention_name>
    <description>cytarabine 20mg bid for 10 days.</description>
    <arm_group_label>Low dose cytarabine</arm_group_label>
    <other_name>cytarabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myeloid leukemia except APL

          -  ECOG PS：0-3

          -  Unfit or unwilling to receive intensive therapy

        Exclusion Criteria:

          -  The one who has already received induction therapy no matter what the outcome is.

          -  Active cancer patients who are needed to receive treatment;

          -  Serious uncontrolled infectious diseases(eg.tuberculosis or invasive pulmonary
             aspergillosis）；

          -  Active heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianxiang Wang, MD</last_name>
    <phone>+862223909120</phone>
    <email>wangjx@cams.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chunlin Zhou, MD</last_name>
    <phone>+8613820429085</phone>
    <email>zhouchunlin@cams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Treatment and Diagnosis Center of Leukemia</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianxiang Wang, MD</last_name>
      <phone>+862223909120</phone>
      <email>wangjx@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Chunlin Zhou, MD</last_name>
      <phone>+8613820429085</phone>
      <email>zcl7317@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>May 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jianxiang Wang</investigator_full_name>
    <investigator_title>vice-president</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Aclacinomycins</mesh_term>
    <mesh_term>Aclarubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

